Last reviewed · How we verify
ACT-709478 combined with midazolam — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ACT-709478 combined with midazolam (ACT-709478 combined with midazolam) — Idorsia Pharmaceuticals Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ACT-709478 combined with midazolam TARGET | ACT-709478 combined with midazolam | Idorsia Pharmaceuticals Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ACT-709478 combined with midazolam CI watch — RSS
- ACT-709478 combined with midazolam CI watch — Atom
- ACT-709478 combined with midazolam CI watch — JSON
- ACT-709478 combined with midazolam alone — RSS
Cite this brief
Drug Landscape (2026). ACT-709478 combined with midazolam — Competitive Intelligence Brief. https://druglandscape.com/ci/act-709478-combined-with-midazolam. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab